



Bergenin as a Novel Urate-Lowering Therapeutic Strategy for Hyperuricemia

Mo Chen^{1†}, Chenyi Ye^{2†}, Jianing Zhu¹, Peiyu Zhang¹, Yujie Jiang¹, Xiaoyong Lu^{1*} and Huaxiang Wu^{1*}

¹ Department of Rheumatology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China,

² Department of Orthopedic, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China

OPEN ACCESS

Edited by:

Claudia Fiorillo,
University of Florence, Italy

Reviewed by:

Blanka Stiburkova,
Institute of Rheumatology, Prague,
Czechia

Venkata Saroja Voruganti,
The University of North Carolina
at Chapel Hill, United States

Gregory Tsay,
Chung Shan Medical University,
Taiwan

*Correspondence:

Xiaoyong Lu
luxyzju18@zju.edu.cn
Huaxiang Wu
wuhx8855@zju.edu.cn;
wuhx8855@163.com

[†] These authors have contributed
equally to this work and share first
authorship

Specialty section:

This article was submitted to
Molecular Medicine,
a section of the journal
Frontiers in Cell and Developmental
Biology

Received: 04 May 2020

Accepted: 10 July 2020

Published: 29 July 2020

Citation:

Chen M, Ye C, Zhu J, Zhang P,
Jiang Y, Lu X and Wu H (2020)
Bergenin as a Novel Urate-Lowering
Therapeutic Strategy
for Hyperuricemia.
Front. Cell Dev. Biol. 8:703.
doi: 10.3389/fcell.2020.00703

Bergenin is a C-glucoside of 4-O-methyl gallic acid isolated from several medicinal plants and has multiple biological activities. The aim of this study was to assess the potential usefulness of bergenin in hyperuricemia. We found that bergenin reduced serum urate levels in hyperuricemia mice by promoting renal and gut uric acid excretion. Bergenin treatment increased *Abcg2* expression both in the kidneys and intestine, while the expression of *Slc2a9* was suppressed in the kidney and increased in the intestine. Moreover, bergenin induced *ABCG2* expression in HK-2 and Caco-2 cells, as well as *SLC2A9* in Caco-2 cells, via the activation of *PPAR γ* . Nevertheless, bergenin suppressed *SLC2A9* expression in HK-2 cells by inhibiting the nuclear translocation of p53. Furthermore, bergenin decreased the serum levels of IL-6, IL-1 β , and TNF- α in hyperuricemia mice, and promoted a polarization shift from the M1 to M2 phenotype in RAW264.7 cells. In conclusion, these findings provide evidence supporting the further development of bergenin as a novel therapeutic strategy for hyperuricemia.

Keywords: hyperuricemia, bergenin, *ABCG2*, *SLC2A9*, urate-lowering therapeutic

INTRODUCTION

The global burden of gout remains substantial, and in many parts of the world, its incidence has increased over the past years (Kuo et al., 2015). In 2015–2016, the prevalence of hyperuricemia in the United States was 20.2% (22.8 million) in males and 20.0% (24.4 million) in females (Chen-Xu et al., 2019). Moreover, individuals with asymptomatic hyperuricemia are at high risk of developing a variety of diseases, including gouty arthritis, renal damage, hypertension, diabetes mellitus, and metabolic syndrome (Dalbeth et al., 2019). Recent evidence has shown a link between high urate exposure and an increased inflammatory capacity across several tissues and immune cell types (Joosten et al., 2020). Urate-lowering therapies (ULT), including xanthine oxidase inhibitors and uricosuric drugs, often cause severe side effects. Therefore, according to evidence-based international guidelines, such therapies are only recommended in people with established conditions, such as gout and kidney stones (Dalbeth et al., 2019; Joosten et al., 2020). Hence, the development of safe and effective hyperuricemia therapies remains an unmet clinical need.

Nowadays it has become clearly that altered urate transport, both in the gut and the kidneys, has a central role in the pathogenesis of hyperuricaemia and gout (Dalbeth et al., 2019). Furthermore, genome-wide association studies (GWAS) have identified numerous loci that are associated with hyperuricemia and gout (Kawamura et al., 2019; Nakatochi et al., 2019).

Serum urate levels are primarily regulated by the activity of the four transporters solute carrier family 2, facilitated glucose transporter member (*SLC2A9*), solute carrier family 22 member 12 (*SLC22A12*), solute carrier family 17 member 1 (*SLC17A1*), and ATP-binding cassette transporter, subfamily G, member 2 (*ABCG2*), in the kidneys, and of *ABCG2* in the intestine (Nakayama et al., 2017).

Bergenin is the C-glucoside of 4-O-methyl gallic acid and can be found in several medicinal plants, including *Bergenia crassifolia* and *Corylopsis spicata* (Liang et al., 2017). Bergenin has been reported to have multiple biological activities, including antiarthritic (Jain et al., 2014; Singh et al., 2017), immunomodulatory (Wang et al., 2017; Kumar et al., 2019), antidiabetic (Veerapur et al., 2012), osteogenic (Hou et al., 2019), neuroprotective (Barai et al., 2019; Ji et al., 2019), and wound-healing effects (Mukherjee et al., 2013). Wang et al. (2017) showed that bergenin attenuated colitis by activating the peroxisome proliferator-activated receptor (PPAR) γ . Moreover, Veerapur et al. (2012) found that bergenin exerted the antidiabetic effect and could bind the PPAR ligand-binding domain. PPAR γ regulates the expression of various genes by directly binding to peroxisome proliferator response elements (Mandard and Patsouris, 2013).

Although PPAR γ has been reported to regulate the expression of *ABCG2* (Szatmari et al., 2006; To and Tomlinson, 2013; Wang et al., 2016), the relevance of bergenin as a therapeutic agent for hyperuricemia remains unclear. The aim of this study was to explore the potential clinical usefulness of bergenin in hyperuricemia. To this end, we investigated the effects of bergenin on hyperuricemia *in vitro* and *in vivo*, as well as the potential biological mechanisms underlying these effects.

MATERIALS AND METHODS

Reagents and Antibodies

Bergenin (purity >99%) was purchased from JingZhu Biological Technology (Nanjing, China). Uric acid, allopurinol, yeast polysaccharide, and HEPES were purchased from Sigma-Aldrich (United States). Potassium oxonate (PO), rosiglitazone, GW9662, WR-1065, and Pifithrin- β were purchased from MedChemExpress (United States). Antibodies against acetylated-p53, p53 and PPAR γ were obtained from Cell Signaling Technology (United States). Antibodies against Lamin A/C, Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and β -actin were obtained from Santa Cruz Biotechnology (United States). Antibodies against *SLC2A9* and *ABCG2* were obtained from Novus (United States) and Abcam (United States), respectively. Penicillin/streptomycin and TRIzol reagent were purchased from Invitrogen Life Technologies (United States).

Animals

Male C57BL/6 mice (6–8 weeks old) were provided by the Academy of Medical Sciences of Zhejiang Province. Mice were given *ad libitum* access to food and water. All experiments were conducted in accordance with the Animal Care and Use Committee guidelines of Zhejiang province. All experimental

procedures were approved by the Institutional Animal Care and Use Committee of Zhejiang University.

Control mice were fed a standard diet. To induce hyperuricemia, mice were given 25% yeast polysaccharide (YP) mixed in daily diet and intraperitoneal injected of PO (250 mg/kg) at 8:00 a.m. every day. Mice of the treatment group were subjected to intragastric administration of either of two concentrations (40 or 80 mg/kg) of bergenin, while the same volume of normal saline (NS) was used as a control. Intragastric administration of 25 mg/kg allopurinol was performed as a positive control (Figure 1).

Measurement of Uric Acid and Creatinine in Serum and Urine


To measure the serum uric acid levels (SUA), we collected blood samples 2 h after treatment on days 0, 7, 14, and 21. The day before sacrificing, urine samples were collected from mice with metabolic changes within 24 h. Mice were sacrificed 2 h after the last treatment, and blood samples were collected. Uric acid and creatinine levels in serum and urine were determined using the phosphotungstic acid method and a Jaffe reaction kit, respectively (Nanjing Jiancheng Biological Technology Co., Ltd., China). Fractional excretion of urate (FEur) was calculated as per a previously reported method (Perez-Ruiz et al., 2002): $FEur = (Uur\ Scr)/(Sur\ Ucr) \times 100\%$. Sur, serum urate level; Scr, serum creatinine level; Uur, Urinary urate level; Ucr, Urinary creatinine level.

Transintestinal Urate Transport Analysis

Intestinal urate excretion was determined according to a previously described method (Ichida et al., 2012). Briefly, after overnight fasting, mice were anesthetized with 2% isoflurane inhalation using an isoflurane delivery system 2 h after the last treatment. Subsequently, mice were cannulated with polyethylene tubing at the upper duodenum and middle jejunum, making an intestinal loop at the upper half of the intestine. The intestinal contents were slowly removed by saline and air. Efflux buffer (saline containing 0.3 mM PO) was added into the intestinal loop; the bugger was collected at the indicated time points, and urate concentrations were quantified. Intestinal urate excretion was calculated using the following equation: intestinal urate excretion = (urate concentration in the intestinal loop) \times (volume of efflux buffer in the intestinal loop) (length of the whole small intestine/length of the intestinal loop). Urate concentration was determined using the QuantiChrom Uric Acid Assay Kit (Bioassay Systems, United States).

Histological Examination

After mice were sacrificed, kidney tissues were collected and cleaned, followed by fixation in 4% paraformaldehyde for at least 48 h at room temperature. Specimens were embedded in paraffin wax, and 3-mm thick sections were prepared. After mounting the sections onto polylysine-coated slides, hematoxylin and eosin, as well as Masson's stainings were performed on consecutive tissue sections. Images were obtained using a microscope.



Xanthine Oxidase Activity Measurement

Xanthine oxidase (XO) activity in liver tissues was measured using a Xanthine Oxidase Activity Assay Kit (Sigma, United States) according to the manufacturer's instructions. XO activity was determined by a coupled enzyme assay, which results in a colorimetric (570 nm) fluorometric product, which is proportional to the hydrogen peroxide generated. XO activity was expressed as nanomoles of uric acid per min per mg of total protein (mU/mg).

Cytokine Measurement

Blood samples were collected 2 h after the last treatment. The concentrations of IL-1 β , TNF α , IL-6, IL-10, and IL-1Ra were determined using the respective ELISA kits (BOSTER, China for IL-1Ra and NEOBIOSCIENCE, China for the rest) according to the manufacturer's instructions.

Cell Culture

HK-2, Caco-2, and RAW264.7 cells were kindly provided by Stem Cell Bank, Chinese Academy of Sciences (Shanghai, China). HK-2 cells were maintained in Dulbecco's modified Eagle medium (DMEM)/F12 medium (Gibco, United States) containing 10% fetal bovine serum (FBS; Gibco, Australia). Caco-2 and RAW264.7 cells were cultured in high-glucose DMEM (Gibco, United States) supplemented with 10% FBS (Gibco,

Australia). Cells were maintained in a humidified incubator containing 5% CO₂ at 37°C.

Inhibitors were dissolved in DMSO or double-distilled water (ddH₂O). Prior to treatments, we cultured cells overnight in serum-free medium to induce growth arrest. Cells were treated with bergenin and indicated inhibitors in a humidified incubator containing 5% CO₂ at 37°C, with or without stimulation with soluble uric acid for an additional 12 h. The final concentrations and incubation times were as follow: rosiglitazone (30 μ M, 2 h), GW9662 (10 μ M, 2 h), WR-1065 (1 mM, 2 h), and Pifithrin- β (10 μ M, 2 h). Following the addition of HEPES at a final concentration of 25 mM, cells were treated with uric acid or the solvent (10 mM NaOH). The solution was filtered through a 0.22- μ m pore size filter (Millipore, Shanghai, China) before use.

CCK-8

The effect of bergenin on the viability of HK-2 and Caco-2 cells was evaluated using the CCK8 assay. Cells were treated with different concentrations of bergenin, followed by incubation with 10% CCK-8 (Dojindo, Kumamoto, Japan) in 100 μ L of high-glucose serum-free DMEM for 4 h at 37°C. Absorbance at 450 nm was measured on a microplate reader (ELX808; BioTek, Winooski, VT, United States).

Extraction of Subcellular Fractions

For total protein extraction, cells were washed with ice-cold phosphate-buffered saline (PBS) and lysed in

radioimmunoprecipitation assay (RIPA) lysis buffer supplemented with proteasome inhibitors (Beyotime, Shanghai, China).

Nuclear and cytoplasmic extracts were prepared using the NE-PER Nuclear Cytoplasmic Extraction Reagent Kit (Pierce, Rockford, IL, United States) according to the manufacturer's instructions. Briefly, cells were washed in PBS. Ice-cold CER I buffer was added to the cell pellet and vortexed vigorously for 15 s. After a 10-min incubation on ice, ice-cold CER II buffer was added to the cells. Samples were incubated on ice for 1 min, followed by centrifugation for 5 min at $16,000 \times g$. Subsequently, the supernatant containing the cytoplasmic extract was immediately transferred to a pre-chilled tube.

Western Blot Analysis

Equal amounts of protein were separated by 8–12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto polyvinylidene fluoride membranes (Millipore). Membranes were blocked in 5% non-fat dry milk for 2 h at room temperature, followed by overnight incubation at 4°C with the appropriate primary antibody: GAPDH (1:2000), ABCG2 (1:1000), SLC2A9 (1:1000), PPAR γ (1:1000), p53 (1:1000), acetylated-p53, β -actin (1:1000), or Lamin A/C (1:1000). Horseradish peroxidase (HRP)-conjugated goat anti-rabbit or goat anti-mouse IgG (1:5000; Cell Signaling Technology) secondary antibody was applied for 1 h at room temperature. Membranes were covered with enhanced chemiluminescence solution (Millipore) and exposed to film. Signal intensity was measured using the Bio-Rad XRS chemiluminescence detection system (Bio-Rad, Hercules, CA, United States).

Immunofluorescence

HK-2 and Caco-2 cells were seeded onto 24-well plates. After treatment, cells were fixed in 4% paraformaldehyde for 15 min, washed with PBS, and permeabilized with or without 0.1% Triton X-100 (Beyotime) for 30 min. After blocking in 10% goat serum for 60 min, slides were incubated with a rabbit p53 antibody (1:200) overnight at 4°C. Samples were then incubated with Alexa Fluor 488-conjugated goat anti-rabbit IgG antibody (Invitrogen) for 2 h, and nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI, Sigma, United States). Samples were observed under a fluorescence microscope (Leica, Solms, Germany).

Real-Time Quantitative Polymerase Chain Reaction (RT-qPCR)

Total RNA was isolated using TRIzol reagent (Invitrogen) and quantified by measuring the absorbance at 260 nm (NanoDrop 2000; Thermo Fisher Scientific, Waltham, MA, United States). Complementary single-stranded DNA was synthesized from total RNA by reverse transcription (PrimerScript RT Master Mix, TaKaRa, Kyoto, Japan). RT-qPCR reactions were prepared using the SYBR Premix Ex Taq Kit (TaKaRa) in a total volume of 20 μ L. All reactions were prepared in duplicates and were run on an ABI StepOnePlus System (Applied Biosystems, Warrington, United Kingdom). The PCR temperature cycling conditions were

as follows: 95°C for 30 s followed by 40 cycles at 95°C for 5 s and 60°C for 30 s. Relative gene expression was analyzed using the $2^{-\Delta\Delta C_t}$ method. The primer sequences used are provided in **Supplementary Table S1**.

Transfection of Cells With Small Interfering RNA (siRNA)

Cells were seeded onto 6-well plates and cultured overnight in DMEM/F12 or DMEM without FBS and antibiotics. siRNA transfections were carried out using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. Briefly, 10 μ L of siRNA and 5 μ L of Lipofectamine 2000 reagent were combined in a total of 300 μ L of Opti-MEM I (Gibco, Invitrogen). Thereafter, 700 μ L of Opti-MEM I was added to the mixture, and the mixture was added to each well. After incubation for 6 h, fresh DMEM or DMEM/F12 containing 10% FBS was added to each well. Cells were incubated for an additional 48–72 h. PPAR γ siRNAs and the negative control siRNAs were purchased from GenePharma (Shanghai, China).

Luciferase Reporter Assay

Cells were transfected with luciferase reporter constructs PPAR γ -Luc (Promega, United States) or p53-Luc (Promega, United States) as previously described (Ye et al., 2019). Cells were then treated with uric acid (UA, 8 mg/dL) and/or bergenin for 12 h. Subsequently, luciferase activity was measured using a luciferase assay system (Promega, United States).

Statistical Analysis

Statistical analysis was performed using the SPSS statistical software for Windows, version 19.0 (IBM, Armonk, NY, United States). All experiments were performed at least in triplicate, and the data were expressed as mean \pm standard error of the mean (SEM). Statistical significance was determined using one-way analysis of variance (ANOVA) followed by Fisher's Least Significant Difference (LSD) test when comparing more than two groups. P values ≤ 0.05 were considered statistically significant. The correlation between variables was evaluated by the Pearson correlation test. Two-sided P values < 0.05 were considered statistically significant.

RESULTS

Bergenin Ameliorates Hyperuricemia in Mice Treated With Potassium Oxonate (PO) and Yeast Polysaccharide (YP)

The procedure followed to develop a hyperuricemia mouse model is illustrated in **Figure 1**. Compared with control mice, SUA levels were significantly higher in hyperuricemia mice after day 7, and remained elevated between day 14 ($407.41 \pm 79.09 \mu\text{mol/L}$ vs. $194.07 \pm 25.85 \mu\text{mol/L}$; $P < 0.01$) and day 21 ($439.39 \pm 48.11 \mu\text{mol/L}$ vs. $220.60 \pm 35.28 \mu\text{mol/L}$; $P < 0.01$). SUA elevation was suppressed by bergenin (80 mg/kg) and allopurinol administration. While bergenin at 80 mg/kg profoundly decreased SUA levels ($253.18 \pm 31.74 \mu\text{mol/L}$)

compared to hyperuricemia mice, no significant difference was observed at day 21 after administration of 40 mg/kg bergenin ($397.39 \pm 52.69 \mu\text{mol/L}$; **Figure 2A**). This finding suggests that the effects of bergenin are dose-dependent to some degree. It is worth noting that SUA level of the Bergenin (80 mg/kg) group stabilized at baseline levels from day 1 to day 21. As expected, SUA levels were significantly lower in allopurinol-treated mice (positive control) compared with control mice. No significant differences in SUA levels were observed between the mice in the bergenin (80 mg/kg) group and the allopurinol group.

Scr, FEur, intestinal urate excretion rate, and hepatic XO activity were assessed at day 21. Scr levels were higher in hyperuricemia mice compared with control mice; however, the difference did not reach statistical significance ($P > 0.05$) (**Figure 2B**). In hyperuricemic mice, FEur was decreased; bergenin (40 mg/kg, 80 mg/kg) treatment rescued FEur. Furthermore, urate excretion from the intestine was significantly increased in mice treated with bergenin (80 mg/kg) compared with hyperuricemic mice ($P < 0.01$; **Figure 2D**). While allopurinol reduced hepatic XO activity ($P < 0.01$), it did not affect uric acid excretion in the kidneys and intestine ($P > 0.05$) compared with hyperuricemia mice (**Figures 2C–E**). Additionally, bergenin had no effect on XO activity in liver and jejunum (**Figure 2E, Supplementary Figure S1**).

Histological analysis revealed that the ultrastructure of the kidneys was intact in mice treated with PO and YP. Compared with control mice, degeneration and necrosis were observed in tubular epithelial cells of hyperuricemic mice (**Figure 2F**). Bergenin (80 mg/kg) and allopurinol treatment ameliorated PO- and YP-induced pathological lesions. No histological changes were observed in the intestine of hyperuricemic or bergenin-treated mice (**Supplementary Figure S2**).

Bergenin Regulates the Expression of Urate Transporters in the Kidney

To determine the effects of bergenin on uric acid excretion in the kidneys, we analyzed the expression of urate transporters involved in urate export and reuptake in the kidney. We found no significant differences in the mRNA levels of the genes encoding urate transporter 1 (*Urat1*) and PDZ domain-containing 1 (*Pdzk1*) among the different groups ($P > 0.05$; **Figure 3A**). *Abcg2* expression was lower in hyperuricemic mice compared with control mice; nevertheless, its expression in hyperuricemic mice was rescued by bergenin (40 mg/kg, 80 mg/kg) treatment, both at the mRNA and protein levels ($P < 0.01$) (**Figures 3A,E**). Bergenin at 80 mg/kg and 40 mg/kg resulted in 2-fold and 1.5-fold increases in *Abcg2* mRNA levels, respectively.

In contrast, *Slc2a9* expression was higher in hyperuricemic mice compared with control mice, and bergenin (80 mg/kg) suppressed *Slc2a9* expression, which was evident both at the mRNA and protein levels ($P < 0.01$). Although bergenin treatment (40 mg/kg) decreased SLC2A9 protein levels ($P < 0.05$, compared to the model group), no difference was observed at the mRNA level (**Figures 3A,E**). Hyperuricemic mice exhibited a reduction in PPAR γ expression ($P < 0.01$, compared to control

mice), PPAR γ expression was restored by bergenin (40 mg/kg, 80 mg/kg; **Figure 3E**).

Bergenin Regulates the Expression of Urate Transporters in the Intestine

RT-qPCR analyses revealed no significant differences in the expression of *Pdzk1* and solute carrier family 17 member 3 (*Slc17a3*) in the intestine among the groups ($P > 0.05$; **Figures 3B–D**). In the colon, bergenin (40 mg/kg, 80 mg/kg) significantly increased *Abcg2* mRNA and protein levels (**Figures 3B,F**). Hyperuricemic mice had lower *Abcg2* mRNA and protein levels compared with the control group, which were restored by bergenin (40 mg/kg, 80 mg/kg) treatment (**Figures 3C,G**). In the jejunum, the expression of *Abcg2* was increased in hyperuricemic mice, and its expression was elevated by bergenin in a dose-dependent manner, both at the mRNA and protein levels (**Figures 3D,H**). These RT-qPCR and western blot findings were also confirmed by immunofluorescence (**Supplementary Figure S3**).


Compared to control mice, hyperuricemic mice exhibited decreased expression of *Slc2a9* in the ileum and jejunum, both at the mRNA and protein levels ($P < 0.01$). Administration of bergenin significantly restored *Slc2a9* expression in the ileum and jejunum (**Figures 3C,D,G,H**). The mRNA levels of *Slc2a9* were increased by approximately 2-fold and 4-fold after administration of bergenin at 40 and 80 mg/kg, respectively, suggesting a dose-dependent effect. On the other hand, RT-qPCR and western blot analyses showed no changes in *Slc2a9* expression in the colon (**Figures 3B,F**). SLC2A9 expression in intestine was further confirmed by immunofluorescence (**Supplementary Figure S3**).

PPAR γ was expressed at lower levels in the ileum and jejunum of hyperuricemic mice ($P < 0.01$, compared with control mice), but not in the colon. Bergenin treatment enhanced PPAR γ expression in a dose-dependent manner (**Figures 3F–H**).

Bergenin Reduces Pro-inflammatory Cytokine Serum Levels

Several studies suggested that hyperuricemia and soluble uric acid levels are associated with systemic inflammation (Joosten et al., 2020). Therefore, we investigated the effects of bergenin on the serum levels of several inflammatory cytokines. IL-1 β , TNF- α , and IL-6 serum levels were significantly increased in hyperuricemic mice; bergenin treatment reduced the serum levels of these cytokines. Notably, bergenin at 80 mg/kg reduced the serum levels of IL-1 β , TNF- α , and IL-6 by 16%, 25%, and 57%, respectively (**Figures 4A,C,E**). In contrast, no significant difference was observed in the serum levels of IL-1Ra or IL-18 (**Figures 4G,I**). Additionally, SUA levels were positively correlated with IL-1 β , TNF- α and IL-6 serum levels and were negatively correlated with those of IL-1Ra (**Figures 4B,D,F,H**). No correlation between SUA and IL-18 (**Figure 4J**).

To gain further insight into the effects of bergenin on inflammatory responses, we treated RAW267.4 cells with UA (8 mg/dL) or bergenin (50 μM). Exposure to UA polarized RAW267.4 cells toward an inflammatory (M1) phenotype with upregulation of inducible nitric oxide synthase (*iNos*)



and downregulation of *Il-10*. In contrast, bergenin treatment polarized RAW267.4 cells toward an anti-inflammatory (M2) phenotype, with high expression of Arginase-1 (*Arg-1*), *Il-10*, and *CD206* and low expression of *Tnf- α* and *iNos*. RAW267.4 cells pretreated with bergenin prior to UA exposure acquired an M2 phenotype, with increased *Arg-1*, *Il-10*, and *CD206* expression and low *Tnf- α* and *iNos* expression (Figure 4K).

Bergenin *in vitro* Treatment Regulates the Expression of ABCG2 and SLC2A9 in HK-2 Human Renal Proximal Tubular Epithelial Cells

We found that bergenin at 10–100 μM did not affect the viability of HK-2 cells (Figure 5A). Hence, we pretreated HK-2 cells with 10, 30, 50, or 100 μM bergenin for 2 h, followed by treatment with 8 mg/dL UA for 10 h. UA decreased *ABCG2* expression at the mRNA and protein level ($P < 0.05$, compared to the control group). UA-mediated *ABCG2* downregulation was rescued by bergenin treatment (50 and 100 μM). In contrast, *SLC2A9* mRNA and protein levels were increased after UA treatment ($P < 0.05$, compared to the control group). Pretreatment with bergenin (50 and 100 μM) suppressed UA-induced *SLC2A9* upregulation (Figures 5B,C); however, lower concentrations of bergenin did not affect *SLC2A9* expression. No significant increase was observed in *ABCG2* and *SLC2A9* expression in cells treated with 30 μM bergenin alone (Figures 5B,C).

Bergenin Promotes ABCG2 Expression by Activating PPAR γ in HK-2 Cells


Luciferase reporter assays revealed that UA significantly reduced the expression and transcriptional activity of *PPAR γ* , both

of which were restored by bergenin (Figures 5C,D). siRNA-mediated *PPAR γ* silencing decreased the mRNA and protein levels of *ABCG2*. Moreover, bergenin treatment failed to enhance *ABCG2* expression after *PPAR γ* knockdown. *PPAR γ* silencing did not affect the expression of *SLC2A9*, regardless of the presence of bergenin (Figures 5E,F).

Similarly to bergenin, pretreatment of HK-2 cells with the *PPAR γ* agonist rosiglitazone before stimulation with UA increased the expression of *PPAR γ* and *ABCG2*. In contrast, pretreatment with the *PPAR γ* antagonist GW9662 enhanced the UA-mediated downregulation of *PPAR γ* and *ABCG2* (Figure 5G). Additionally, bergenin failed to restore *ABCG2* expression in cells treated with GW9662 and UA (Figure 5G). These results suggest that bergenin regulates the expression of *ABCG2* by activating *PPAR γ* .

Bergenin Reduces SLC2A9 Expression by Diminishing Nuclear Translocation of p53 in HK-2 Cells

As the previous research indicated *SLC2A9* was a direct target gene of *p53* (Itahana et al., 2015), we next investigated the effects of bergenin and UA on *p53* signaling. Although bergenin and UA had no effects in the total *p53* and acetylated *p53* levels (Figure 5H), UA significantly decreased *p53* levels in the cytoplasm and increased its levels in the nucleus. These results suggest that UA promotes *p53* protein translocation from the cytoplasm to the nucleus. Interestingly, bergenin suppressed nuclear translocation of *p53* (Figure 5H). Immunofluorescence and luciferase reporter analyses confirmed these results (Figures 5I,J).



Pifithrin- β (PFT- β), a potent *p53* inhibitor, significantly suppressed the UA-induced SLC2A9 upregulation. On the other hand, the *p53* agonist WR-1065 reinforced SLC2A9 upregulation. Bergenin treatment failed to suppress SLC2A9 expression in HK-2 cells treated with WR-1065 and UA (Figure 5K).


Bergenin *in vitro* Treatment Promotes the Expression of ABCG2 and SLC2A9 in Intestinal Epithelial Cells

We next used Caco-2 cells as an *in vitro* model of human intestinal epithelial cells to examine the effects of bergenin on intestinal urate transporters. We found that treatment with bergenin at 10–100 μ M for 12 h had no effects on the viability of Caco-2 cells (Figure 6A). We then pretreated Caco-2 cells with bergenin for 2 h, followed by treatment with UA at 8 mg/dL for 10 h. UA increased ABCG2 mRNA and protein levels and downregulated SLC2A9 levels. Treatment with bergenin alone increased the protein levels of ABCG2 and SLC2A9. Compared to cells treated with UA alone,

ABCG2 and SLC2A9 were significantly upregulated when cells were treated with UA and 100 μ M bergenin (P < 0.01) (Figures 6B,C).

Bergenin Promotes ABCG2 and SLC2A9 Expression by Activating PPAR γ in Caco-2 Cells

Similar to HK-2 cells, UA significantly inhibited PPAR γ activity in Caco-2 cells, which was restored by bergenin (Figures 6C,D). Interestingly, siRNA-mediated PPAR γ silencing reduced the expression of both ABCG2 and SLC2A9. In addition, bergenin treatment failed to enhance ABCG2 and SLC2A9 expression after PPAR γ silencing (Figures 6E,F). PPAR γ activation by rosiglitazone significantly enhanced the UA-mediated ABCG2 and SLC2A9 upregulation (P < 0.01). In contrast, pretreatment with GW9662 enhanced the UA-mediated downregulation of PPAR γ , ABCG2, and SLC2A9. Furthermore, bergenin failed to restore ABCG2 and SLC2A9 expression in cells treated with GW9662 and UA (Figure 6G).



Bergenin Does Not Affect the p53 Signaling Pathway in Caco-2 Cells

Bergenin treatment did not alter the total p53 and acetylated p53 levels in Caco-2 cells (Figure 6H). Additionally, immunofluorescence analyses indicated that bergenin did not promote nuclear translocation of p53 (Figure 6I).

DISCUSSION

As serum urate levels are associated with the development of gout, interventions that reduce serum urate concentrations have been investigated for their potential to prevent gout (Dalbeth et al., 2019). In this study, we assessed the effect of bergenin on hyperuricemia using a mouse model. We showed for the first time that bergenin has uricosuric properties, reducing serum urate levels in hyperuricemic mice. We also provided evidence that its urate-lowering effects are mediated by increasing *Abcg2* expression in the kidneys and intestine, as well as *Slc2a9* downregulation in the kidneys. Furthermore, we demonstrated that bergenin downregulates IL-6, IL-1 β , and TNF- α serum levels in hyperuricemic mice and polarizes RAW264.7 cells toward an M2 phenotype.

ABCG2 is a high-capacity urate exporter expressed in the intestine and kidneys, and ABCG2 dysfunction strongly increases serum urate levels and the risk of gout development (Ichida et al., 2012; Dalbeth et al., 2019). In this study, we

found that although *Abcg2* expression was increased in the jejunum, its levels were decreased in the kidneys and ileum of hyperuricemic mice. After treatment with bergenin, *Abcg2* was significantly upregulated in the kidneys, jejunum, ileum, and colon, enhancing renal and intestine urate excretion. These findings may partly explain the anti-hyperuricemic effects of bergenin. *PPAR γ* is a ligand-regulated transcription factor involved in various pathophysiological processes, including metabolic, inflammatory responses, and tumorigenesis (Berger and Moller, 2002; Mandard and Patsouris, 2013). Herein, we showed that *PPAR γ* expression was decreased under high-UA conditions both *in vitro* and *in vivo*. Importantly, bergenin restored *ABCG2* expression by activating *PPAR γ* . These findings suggest that *PPAR γ* enhances *ABCG2* expression, which is consistent with previous studies (Szatmari et al., 2006; Wang et al., 2016). It is noteworthy that in Caco-2 cells, although *PPAR γ* was decreased after treatment with UA, *ABCG2* expression was upregulated. This could be explained by the fact that UA is not a specific *PPAR γ* antagonist. In a previous study, we showed that soluble UA induced *ABCG2* expression in Caco-2 cells via the TLR4-NLRP3 inflammasome and PI3K/Akt signaling pathways (Chen et al., 2018). Additionally, the *ABCG2* is the only associated locus with the early onset and/or a family history (Stiburkova et al., 2019). And it has been reported (Roberts et al., 2017) *ABCG2* rs2231142 predicts a poor response to first-line ULT, allopurinol. We will verify the impact of bergenin in the case of *ABCG2* variants with reduced function in the future.




FIGURE 5 | Bergenin regulates the expression of ABCG2 and SLC2A9 in HK-2 cell lines. **(A)** HK-2 cell lines were treated with bergenin (10, 30, 50, or 100 μ M) for 12 h, and cell viability was determined by the CCK8 assay. **(B)** HK-2 cell lines were pretreated with bergenin (0, 30, 50, or 100 μ M) for 2 h, followed by treatment with 8 mg/dL uric acid (UA) for 10 h. Relative mRNA levels of ABCG2 and SLC2A9 were determined by RT-qPCR. **(C)** Representative western blot showing ABCG2, SLC2A9, and PPAR γ protein levels. Protein levels were normalized to GAPDH. **(D)** Transcriptional activity of PPAR γ , as determined by luciferase assay. **(E)** Cells were transfected with PPAR γ siRNA or scrambled siRNA for 48 h. Cells were then pretreated with or without 50 μ M bergenin for 2 h, followed by exposure to 8 mg/dL UA for another 10 h. Relative mRNA levels of ABCG2, SLC2A9, and PPAR γ were determined by RT-qPCR. **(F)** Representative western blot showing ABCG2, SLC2A9, and PPAR γ protein levels. Protein levels were normalized to GAPDH. **(G)** Cells were pretreated with bergenin (50 μ M) or rosiglitazone (PPAR γ agonist) for 2 h, followed treatment with 8 mg/dL UA for another 10 h, with or without GW9662 (PPAR γ inhibitor). ABCG2, SLC2A9, and PPAR γ protein levels were determined by western blotting. Protein levels were normalized to GAPDH. **(H)** Total p53 and acetylated p53 levels were measured by western blot analysis. Protein levels were normalized to GAPDH. Cytoplasmic and nuclear extracts were prepared for western blot analyses. Cytoplasmic protein levels were normalized to GAPDH, whereas nuclear protein levels were normalized to Lamin A/C. **(I)** Representative immunofluorescence images (magnification, \times 400) showing p53 expression (green). Nuclei were stained with DAPI (blue). Scale bar = 50 μ m. **(J)** Transcriptional activity of p53, as determined by luciferase assay. **(K)** Cells were pretreated with bergenin (50 μ M) or the p53 inhibitor Pifithrin- β (PFT- β) for 2 h, followed by treatment with 8 mg/dL UA for another 10 h, with or without WR-1065 (p53 agonist). ABCG2, SLC2A9, and p53 protein levels were determined by western blot analysis. Protein levels were normalized to GAPDH. Data are presented as mean \pm SEM. * P < 0.05 and ** P < 0.01, n = 3.





FIGURE 6 | Bergenin regulates the expression of ABCG2 and SLC2A9 in Caco-2 cell lines. **(A)** Cells were treated with bergenin (10, 30, 50, and 100 μ M) for 12 h, and cell viability was determined by the CCK8 assay. **(B)** Caco-2 cells were pretreated with 0, 30, 50, or 100 μ M bergenin for 2 h, followed by treatment with 8 mg/dL UA for 10 h. Relative mRNA levels of ABCG2, and SLC2A9, as determined by RT-qPCR. **(C)** Representative western blots showing ABCG2, SLC2A9, and PPAR γ protein levels. Protein levels were normalized to GAPDH. **(D)** Transcriptional activity of PPAR γ , as determined by luciferase assays. **(E)** Cells were transfected with PPAR γ siRNA or scrambled siRNA for 48 h. Cells were then pretreated with or without 100 μ M bergenin for 2 h, followed by incubation with 8 mg/dL UA for another 10 h. Relative mRNA levels of ABCG2, SLC2A9, and PPAR γ , as determined by RT-qPCR. **(F)** Representative western blots showing ABCG2, SLC2A9, and PPAR γ protein levels. Protein levels were normalized to GAPDH. **(G)** Cells were pretreated with bergenin (100 μ M) or rosiglitazone (PPAR γ agonist) for 2 h followed by incubation with 8 mg/dL UA for another 10 h, with or without GW9662 (PPAR γ inhibitor). ABCG2, SLC2A9, and PPAR γ protein levels were determined by western blotting. Protein levels were normalized to GAPDH. **(H)** Total p53 and acetylated p53 levels were determined by western blot analysis. Protein levels were normalized to GAPDH. **(I)** Representative immunofluorescence images (magnification, \times 400) showing p53 expression (green). Nuclei were stained with DAPI (blue). Scale bar = 50 μ m.

SLC2A9 is widely expressed, including in the liver, kidneys, intestine, brain, placenta, lungs, and peripheral leucocytes (Phay et al., 2000; DeBosch et al., 2014). In kidneys, *SLC2A9* is

responsible for reabsorption of urate at the basolateral membrane in the proximal renal tubule (Dinour et al., 2010). Herein, we demonstrated that bergenin decreased *SLC2A9* expression by



inhibiting the nuclear translocation of p53, which indicated that bergenin might not only have effect on urate excretion, but also urate reabsorption in the kidneys. Consistently, Itahana et al. (2015) showed that *SLC2A9* was a direct target gene of the tumor suppressor *p53*. Interestingly, we found no association between *SLC2A9* and *p53* levels in Caco-2 cells. Caco-2 is a well-characterized human colon adenocarcinoma cell line widely used to investigate mechanisms of drug absorption or characterize intestinal transporters. Caco-2 cells harbor *p53* mutations (Lee et al., 2008; Sun et al., 2008), which is a limitation of using this cell line model to assess the relevance of *p53* pathway in the anti-hyperuricemic effects of bergenin. In addition to the liver and kidneys, *SLC2A9* is also expressed on the apical and basolateral gut enterocyte membranes in mice (Lu et al., 2019). Gut enterocyte-specific *Slc2a9*-knockout mice exhibited increased serum urate levels with impaired enterocyte urate transport kinetics. Moreover, these mice developed early onset metabolic syndromes, including hypertension, dyslipidemia, and hyperinsulinemia, suggesting a role of *Slc2a9* in regulating enterocyte urate clearance (DeBosch et al., 2014). The upregulation of *Slc2a9* in the jejunum and ileum reported herein could have contributed to increased urate excretion from the intestine observed after bergenin treatment.

We also detected the xanthine oxidase activity in ileum and jejunum besides livers. The xanthine oxidase activity was almost undetectable in the ileum. No significant difference were found in the jejunum among the groups (**Supplementary Figure S1B**). However, Yoon et al. (2016) have shown *in vivo* XO inhibitory and antihyperuricemic effects of *Corylopsis coreana* Uyeki, containing and identified bergenin as one of constituents. As a herbal medicine, *Corylopsis coreana* Uyeki might also include

some other constituents responsible for the XO inhibitory activity. Synergizing action of a combination of several active components may be another possibility.

The crosstalk between *PPAR γ* and *SIRT1* plays an important role in the regulation of metabolism and inflammation (Han et al., 2010; Chou et al., 2017). Furthermore, p53 acetylation at Lys382, the primary target site of *SIRT1*, increases the ability of p53 to activate transcription (Feng et al., 2015; Nakamura et al., 2017). Therefore, we used siRNAs targeting *SIRT1* to explore the interaction. *SIRT1* silencing did not affect the expression of *PPAR γ* , *ABCG2*, or *SLC2A9* in HK-2 and Caco-2 cells, regardless of exposure to bergenin (**Supplementary Figure S4**).

Increasing evidence suggests that not only crystalline urate, but soluble urate could promote metabolic inflammation, activate innate immunity, and trigger epigenetic alterations that amplify pro-inflammatory responses (Crişan et al., 2017; Joosten et al., 2020). Studies in patients with asymptomatic hyperuricemia have shown that increased serum urate concentrations are associated with inflammatory responses, including increased IL-6, IL-1 β , TNF- α , and IL-18 levels and decreased IL-1Ra and IL-10 levels (Crişan et al., 2016; Crişan et al., 2017). Kim et al. (2015) reported that hyperuricemia induced NLRP3 activation in macrophages, accelerated macrophage recruitment, and promoted M1 phenotype polarization, contributing to diabetic nephropathy progression. These findings suggest that in addition to urate-lowering therapies, immunomodulatory therapies may also be helpful in hyperuricemia treatment. Bergenin is a plant-derived compound with well-documented anti-inflammatory properties (Veerapur et al., 2012). Notably, bergenin inhibited collagen-induced arthritis and ameliorated experimental colitis in mice by reducing the serum levels of

IL-2, IL-6, and TNF- α (Jain et al., 2014; Wang et al., 2017; Lopes de Oliveira et al., 2019). In this study, we found that the serum levels of IL-1 β , TNF- α , and IL-6 were increased in hyperuricemic mice and positively correlated with SUA. Bergenin treatment reduced the serum levels of IL-1 β , TNF- α , and IL-6 in hyperuricemic mice.

M1 macrophages are characterized by TNF- α and iNOS expression and mediate tissue damage and initiate inflammatory responses by secreting high levels of various pro-inflammatory cytokines, including IL-1 α , TNF- α , and IL-1 β (Shapouri-Moghaddam et al., 2018). To protect against excessive tissue damage and inflammation, macrophages can acquire an M2 phenotype, expressing several anti-inflammatory molecules, such as IL-10 and IL-1Ra (Shapouri-Moghaddam et al., 2018). In this study, we showed that bergenin treatment *in vitro* induced *Il-10*, *CD206* and *Arg-1* expression in macrophages while decreasing *Tnf- α* and *iNos* expression at the same time, suggesting a shift from the M1 to M2 phenotype. M2 polarization in macrophages after bergenin treatment can, therefore, be one of the mechanisms responsible for the anti-inflammatory effects of bergenin reported in previous studies. Nevertheless, the in-depth mechanisms involved in the inflammatory effects of bergenin in hyperuricemia need further investigation.

CONCLUSION

In summary (Figure 7), these findings indicated that bergenin not only can promote renal and gut uric acid excretion via regulating the expression of *ABCG2* and *SLC2A9* but also attenuate inflammation and induce a macrophage polarization shift from the M1 phenotype to M2. Thus, bergenin is a promising candidate as a novel therapeutic strategy for hyperuricemia, either for supplement of the existing ULT or potential intervention in metabolic inflammation.

REFERENCES

- Barai, P., Raval, N., Acharya, S., Borisa, A., Bhatt, H., and Acharya, N. (2019). Neuroprotective effects of bergenin in Alzheimer's disease: investigation through molecular docking, *in vitro* and *in vivo* studies. *Behav. Brain Res.* 356, 18–40. doi: 10.1016/j.bbr.2018.08.010
- Berger, J., and Moller, D. E. (2002). The mechanisms of action of PPARs. *Annu. Rev. Med.* 53, 409–435. doi: 10.1146/annurev.med.53.082901.104018
- Chen, M., Lu, X., Lu, C., Shen, N., Jiang, Y., Chen, M., et al. (2018). Soluble uric acid increases PDZK1 and ABCG2 expression in human intestinal cell lines via the TLR4-NLRP3 inflammasome and PI3K/Akt signaling pathway. *Arthritis Res. Ther.* 20:20. doi: 10.1186/s13075-018-1512-4
- Chen-Xu, M., Yokose, C., Rai, S. K., Pillinger, M. H., and Choi, H. K. (2019). Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: the National health and nutrition Examination Survey, 2007–2016. *Arthritis Rheumatol.* 71, 991–999. doi: 10.1002/art.40807
- Chou, H. C., Wen, L. L., Chang, C. C., Lin, C. Y., Jin, L., and Juan, S. H. (2017). From the Cover: L-Carnitine via PPARgamma- and Sirt1-dependent mechanisms attenuates epithelial-mesenchymal transition and renal fibrosis caused by perfluorooctanesulfonate. *Toxicol. Sci.* 160, 217–229. doi: 10.1093/toxsci/kfx183

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation, to any qualified researcher.

ETHICS STATEMENT

The animal study was reviewed and approved by Institutional Animal Care and Use Committee of Zhejiang University.

AUTHOR CONTRIBUTIONS

HW and XL contributed to design and funding sources to this study. MC and CY drafted the manuscript. MC, JZ, PZ, and YJ did all the *in vitro* parts of the study. All authors have contributed significantly and read and approved the final manuscript.

FUNDING

This work was supported by the National Natural Science Foundation of China (No. 81571577), Key Research and Development Program of Zhejiang Province (No. 2020C3044), Scientific Research Fund of Zhejiang Provincial Education Department, Medicine and Health Science and Technology Project of Zhejiang Province (No. 2017192934), and Science and Technology Plan Project of Zhejiang Province (No. 2017C37128).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fcell.2020.00703/full#supplementary-material>

- Crisan, T. O., Cleophas, M. C., Oosting, M., Lemmers, H., Toenhake-Dijkstra, H., Netea, M. G., et al. (2016). Soluble uric acid primes TLR-induced proinflammatory cytokine production by human primary cells via inhibition of IL-1Ra. *Ann. Rheum. Dis.* 75, 755–762. doi: 10.1136/annrheumdis-2014-206564
- Crişan, T. O., Cleophas, M. C. P., Novakovic, B., Erler, K., Van De Veerdonk, F. L., Stunnenberg, H. G., et al. (2017). Uric acid priming in human monocytes is driven by the AKT-PRAS40 autophagy pathway. *Proc. Natl. Acad. Sci. U.S.A.* 114, 5485–5490. doi: 10.1073/pnas.1620910114
- Dalbeth, N., Choi, H. K., Joosten, L. A. B., Khanna, P. P., Matsuo, H., Perez-Ruiz, F., et al. (2019). Gout. *Nat. Rev. Dis. Primers* 5:69. doi: 10.1038/s41572-019-0115-y
- DeBosch, B. J., Kluth, O., Fujiwara, H., Schurmann, A., and Moley, K. (2014). Early-onset metabolic syndrome in mice lacking the intestinal uric acid transporter SLC2A9. *Nat. Commun.* 5:4642. doi: 10.1038/ncomms5642
- Dinour, D., Gray, N. K., Campbell, S., Shu, X., Sawyer, L., Richardson, W., et al. (2010). Homozygous SLC2A9 mutations cause severe renal hypouricemia. *J. Am. Soc. Nephrol.* 21, 64–72. doi: 10.1681/ASN.2009040406
- Feng, Y., Liu, T., Dong, S. Y., Guo, Y. J., Jankovic, J., Xu, H., et al. (2015). Rotenone affects p53 transcriptional activity and apoptosis via targeting SIRT1 and H3K9 acetylation in SH-SY5Y cells. *J. Neurochem.* 134, 668–676. doi: 10.1111/jnc.13172

- Han, L., Zhou, R., Niu, J., Mcnutt, M. A., Wang, P., and Tong, T. (2010). SIRT1 is regulated by a PPAR[gamma]-SIRT1 negative feedback loop associated with senescence. *Nucleic Acids Res.* 38, 7458–7471. doi: 10.1093/nar/gkq609
- Hou, W., Ye, C., Chen, M., Li, W., Gao, X., He, R., et al. (2019). Bergenin activates SIRT1 as a novel therapeutic agent for osteogenesis of bone mesenchymal stem cells. *Front. Pharmacol.* 10:618. doi: 10.3389/fphar.2019.00618
- Ichida, K., Matsuo, H., Takada, T., Nakayama, A., Murakami, K., Shimizu, T., et al. (2012). Decreased extra-renal urate excretion is a common cause of hyperuricemia. *Nat. Commun.* 3:764. doi: 10.1038/ncomms1756
- Itahana, Y., Han, R., Barbier, S., Lei, Z., Rozen, S., and Itahana, K. (2015). The uric acid transporter SLC2A9 is a direct target gene of the tumor suppressor p53 contributing to antioxidant defense. *Oncogene* 34, 1799–1810. doi: 10.1038/nc.2014.119
- Jain, S. K., Singh, S., Khajuria, A., Guru, S. K., Joshi, P., Meena, S., et al. (2014). Pyrano-isochromanones as IL-6 inhibitors: synthesis, in vitro and in vivo antiarthritic activity. *J. Med. Chem.* 57, 7085–7097. doi: 10.1021/jm500901e
- Ji, Y., Wang, D., Zhang, B., and Lu, H. (2019). Bergenin ameliorates MPTP-induced Parkinson's disease by activating PI3K/Akt signaling pathway. *J. Alzheimers Dis.* 72, 823–833. doi: 10.3233/JAD-190870
- Joosten, L. A. B., Crisan, T. O., Bjornstad, P., and Johnson, R. J. (2020). Asymptomatic hyperuricaemia: a silent activator of the innate immune system. *Nat. Rev. Rheumatol.* 16, 75–86. doi: 10.1038/s41584-019-0334-3
- Kawamura, Y., Nakaoka, H., Nakayama, A., Okada, Y., Yamamoto, K., Higashino, T., et al. (2019). Genome-wide association study revealed novel loci which aggravate asymptomatic hyperuricaemia into gout. *Ann. Rheum. Dis.* 78, 1430–1437. doi: 10.1136/annrheumdis-2019-215521
- Kim, S. M., Lee, S. H., Kim, Y. G., Kim, S. Y., Seo, J. W., Choi, Y. W., et al. (2015). Hyperuricemia-induced NLRP3 activation of macrophages contributes to the progression of diabetic nephropathy. *Am. J. Physiol. Renal. Physiol.* 308, F993–F1003. doi: 10.1152/ajprenal.00637.2014
- Kumar, S., Sharma, C., Kaushik, S. R., Kulshreshtha, A., Chaturvedi, S., Nanda, R. K., et al. (2019). The phytochemical bergenin as an adjunct immunotherapy for tuberculosis in mice. *J. Biol. Chem.* 294, 8555–8563. doi: 10.1074/jbc.RA119.008005
- Kuo, C. F., Grainge, M. J., Zhang, W., and Doherty, M. (2015). Global epidemiology of gout: prevalence, incidence and risk factors. *Nat. Rev. Rheumatol.* 11, 649–662. doi: 10.1038/nrrheum.2015.91
- Lee, W., Belkhir, A., Lockhart, A. C., Merchant, N., Glaeser, H., Harris, E. I., et al. (2008). Overexpression of OATP1B3 confers apoptotic resistance in colon cancer. *Cancer Res.* 68, 10315–10323. doi: 10.1158/0008-5472.CAN-08-1984
- Liang, C., Pei, S., Ju, W., Jia, M., Tian, D., Tang, Y., et al. (2017). Synthesis and in vitro and in vivo antitumor activity study of 11-hydroxyl esterified bergenin/cinnamic acid hybrids. *Eur. J. Med. Chem.* 133, 319–328. doi: 10.1016/j.ejmech.2017.03.053
- Lopes de Oliveira, G. A., Alarcón De La Lastra, C., Rosillo, M., Castejon Martinez, M. L., Sánchez-Hidalgo, M., Rolim Medeiros, J. V., et al. (2019). Preventive effect of bergenin against the development of TNBS-induced acute colitis in rats is associated with inflammatory mediators inhibition and NLRP3/ASC inflammasome signaling pathways. *Chemico Biol. Interact.* 297, 25–33. doi: 10.1016/j.cbi.2018.10.020
- Lu, J., Dalbeth, N., Yin, H., Li, C., Merriman, T. R., and Wei, W. H. (2019). Mouse models for human hyperuricaemia: a critical review. *Nat. Rev. Rheumatol.* 15, 413–426. doi: 10.1038/s41584-019-0222-x
- Mandard, S., and Patsouris, D. (2013). Nuclear control of the inflammatory response in mammals by peroxisome proliferator-activated receptors. *PPAR Res.* 2013:613864. doi: 10.1155/2013/613864
- Mukherjee, H., Ojha, D., Bharitkar, Y. P., Ghosh, S., Mondal, S., Kaity, S., et al. (2013). Evaluation of the wound healing activity of *Shorea robusta*, an Indian ethnomedicine, and its isolated constituent(s) in topical formulation. *J. Ethnopharmacol.* 149, 335–343. doi: 10.1016/j.jep.2013.06.045
- Nakamura, K., Zhang, M., Gageyama, S., Ke, B., Fujii, T., Sosa, R. A., et al. (2017). Macrophage heme oxygenase-1-SIRT1-p53 axis regulates sterile inflammation in liver ischemia-reperfusion injury. *J. Hepatol.* 67, 1232–1242. doi: 10.1016/j.jhep.2017.08.010
- Nakatochi, M., Kanai, M., Nakayama, A., Hishida, A., Kawamura, Y., Ichihara, S., et al. (2019). Genome-wide meta-analysis identifies multiple novel loci associated with serum uric acid levels in Japanese individuals. *Commun. Biol.* 2:115. doi: 10.1038/s42003-019-0339-0
- Nakayama, A., Nakaoka, H., Yamamoto, K., Sakiyama, M., Shaukat, A., Toyoda, Y., et al. (2017). GWAS of clinically defined gout and subtypes identifies multiple susceptibility loci that include urate transporter genes. *Ann. Rheum. Dis.* 76, 869–877. doi: 10.1136/annrheumdis-2016-209632
- Perez-Ruiz, F., Calabozo, M., Erasuskin, G. G., Ruibal, A., and Herrero-Beites, A. M. (2002). Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output. *Arthritis Rheum.* 47, 610–613. doi: 10.1002/art.10792
- Phay, J. E., Hussain, H. B., and Moley, J. F. (2000). Cloning and expression analysis of a novel member of the facilitative glucose transporter family, SLC2A9 (GLUT9). *Genomics* 66, 217–220. doi: 10.1006/geno.2000.6195
- Roberts, R. L., Wallace, M. C., Phipps-Green, A. J., Topless, R., Drake, J. M., Tan, P., et al. (2017). ABCG2 loss-of-function polymorphism predicts poor response to allopurinol in patients with gout. *Pharmacogenomics J.* 17, 201–203. doi: 10.1038/tpj.2015.101
- Shapouri-Moghaddam, A., Mohammadian, S., Vazini, H., Taghadosi, M., Esmaili, S. A., Mardani, F., et al. (2018). Macrophage plasticity, polarization, and function in health and disease. *J. Cell. Physiol.* 233, 6425–6440. doi: 10.1002/jcp.26429
- Singh, R., Kumar, V., Bharate, S. S., and Vishwakarma, R. A. (2017). Synthesis, pH dependent, plasma and enzymatic stability of bergenin prodrugs for potential use against rheumatoid arthritis. *Bioorg. Med. Chem.* 25, 5513–5521. doi: 10.1016/j.bmc.2017.08.011
- Stiburkova, B., Pavelcova, K., Pavlikova, M., Jesina, P., and Pavelka, K. (2019). The impact of dysfunctional variants of ABCG2 on hyperuricemia and gout in pediatric-onset patients. *Arthritis Res. Ther.* 21:77. doi: 10.1186/s13075-019-1860-8
- Sun, H., Chow, E. C., Liu, S., Du, Y., and Pang, K. S. (2008). The Caco-2 cell monolayer: usefulness and limitations. *Expert Opin. Drug Metab. Toxicol.* 4, 395–411. doi: 10.1517/17425255.4.4.395
- Szatmari, I., Vamosi, G., Brazda, P., Balint, B. L., Benko, S., Szeles, L., et al. (2006). Peroxisome proliferator-activated receptor gamma-regulated ABCG2 expression confers cytoprotection to human dendritic cells. *J. Biol. Chem.* 281, 23812–23823. doi: 10.1074/jbc.M604890200
- To, K. K., and Tomlinson, B. (2013). Targeting the ABCG2-overexpressing multidrug resistant (MDR) cancer cells by PPARgamma agonists. *Br. J. Pharmacol.* 170, 1137–1151. doi: 10.1111/bph.12367
- Veerapur, V. P., Prabhakar, K. R., Thippeswamy, B. S., Bansal, P., Srinivasan, K. K., and Unnikrishnan, M. K. (2012). Antidiabetic effect of *Ficus racemosa* Linn. stem bark in high-fat diet and low-dose streptozotocin-induced type 2 diabetic rats: a mechanistic study. *Food Chem.* 132, 186–193. doi: 10.1016/j.foodchem.2011.10.052
- Wang, J., Zhu, X. X., Liu, L., Xue, Y., Yang, X., and Zou, H. J. (2016). SIRT1 prevents hyperuricemia via the PGC-1alpha/PPARgamma-ABCG2 pathway. *Endocrine* 53, 443–452. doi: 10.1007/s12020-016-0896-7
- Wang, K., Li, Y. F., Lv, Q., Li, X. M., Dai, Y., and Wei, Z. F. (2017). Bergenin, acting as an agonist of PPARgamma, ameliorates experimental colitis in mice through improving expression of SIRT1, and therefore inhibiting NF-kappaB-mediated macrophage activation. *Front. Pharmacol.* 8:981. doi: 10.3389/fphar.2017.00981
- Ye, C., Hou, W., Chen, M., Lu, J., Chen, E., Tang, L., et al. (2019). IGF1BP7 acts as a negative regulator of RANKL-induced osteoclastogenesis and oestrogen deficiency-induced bone loss. *Cell Prolif.* 53:e12752. doi: 10.1111/cpr.12752
- Yoon, I.-S., Park, D.-H., Ki, S.-H., and Cho, S.-S. (2016). Effects of extracts from *Corylopsis coreana* Uyeki (Hamamelidaceae) flos on xanthine oxidase activity and hyperuricemia. *J. Pharm. Pharmacol.* 12, 1597–1603. doi: 10.1111/jph.12626

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Chen, Ye, Zhu, Zhang, Jiang, Lu and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.